View more in
Cancer

Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma

onclive.com
 2021-06-07

Cover picture for the articleTisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial. Tisagenlecleucel (Kymriah) led to a high response rate that proved...

www.onclive.com

Comments / 0

Comments / 0